PILRβ (Paired Immunoglobulin-Like Type 2 Receptor Beta) is an activating immune receptor encoded by the PILRB gene on chromosome 7q22.1. It forms a functional receptor pair with its inhibitory counterpart PILRα, together modulating innate immune cell activation in both peripheral tissues and the central nervous system. PILRβ engagement generates activating signals through association with the DAP12 signaling adaptor, counterbalancing the inhibitory tone set by PILRα. In microglia and myeloid cells, the PILRα/β balance influences phagocytic activity, cytokine production, and neuroinflammatory responses relevant to Alzheimer's disease and other neurodegenerative conditions[1][2].
| Attribute | Value |
|---|---|
| Protein Name | Paired Immunoglobulin-Like Type 2 Receptor Beta |
| Gene Symbol | PILRB |
| UniProt ID | Q9H7E4 |
| Protein Length | 264 amino acids |
| Molecular Weight | ~29 kDa |
| Chromosomal Location | 7q22.1 |
| Subcellular Localization | Cell surface, plasma membrane |
PILRβ is a type I transmembrane glycoprotein containing a single V-type immunoglobulin-like extracellular domain, a transmembrane segment with a positively charged lysine residue, and a short cytoplasmic tail lacking intrinsic signaling motifs. The charged transmembrane residue enables non-covalent association with the ITAM-bearing adaptor protein DAP12 (also called TYROBP), which transduces activating signals upon PILRβ ligand engagement[1:1]. The Ig-like domain adopts a canonical β-sandwich fold and recognizes sialylated O-glycan structures (particularly the Tn and sialyl-Tn antigens) presented on cell surface glycoproteins, including CD99[3]. Unlike PILRα, which contains an ITIM in its cytoplasmic tail for inhibitory signaling, PILRβ relies entirely on DAP12 for signal transduction[2:1].
PILRβ functions as an activating receptor on myeloid lineage cells including monocytes, macrophages, dendritic cells, neutrophils, and microglia. Upon engagement with sialylated glycoprotein ligands, PILRβ recruits DAP12, which becomes phosphorylated on its ITAM tyrosines by Src family kinases. This triggers recruitment and activation of Syk kinase, initiating downstream signaling cascades including PI3K/Akt, PLCγ, and MAPK pathways that promote phagocytosis, cytokine release, and cell survival[1:2][4].
The PILRα/PILRβ receptor pair constitutes a paired receptor system common in immune regulation. Both receptors recognize overlapping O-glycan ligands, but their opposing signaling outputs (inhibitory vs. activating) create a tunable activation threshold. The relative expression levels of PILRα and PILRβ on individual cells determine the net outcome of ligand engagement, providing fine-grained control over immune activation[2:2][3:1].
PILRα (but not PILRβ) has been identified as an entry receptor for herpes simplex virus 1 (HSV-1) through binding to viral glycoprotein B. However, PILRβ may modulate HSV-1 susceptibility indirectly by competing for shared glycan ligands and altering PILRα-mediated viral entry efficiency[5].
In Alzheimer's disease, the PILRα/PILRβ axis has emerged as a modulator of microglial responses to amyloid-β plaques. Genome-wide association studies identified the PILRA/PILRB locus as an AD risk locus, with a protective missense variant (G78R) in PILRα reducing sialic acid binding affinity and altering microglial activation[6][7]. PILRβ-mediated activating signals may promote beneficial microglial phagocytosis of amyloid deposits, while excessive PILRα inhibitory signaling could impair clearance. The balance between these paired receptors likely determines whether microglia adopt a neuroprotective or neurotoxic phenotype in the AD brain[4:1].
PILRβ shares the DAP12 signaling adaptor with TREM2, a major AD risk gene product. Competition for limiting DAP12 molecules may create functional interactions between PILRβ and TREM2 signaling. In microglia where TREM2 is highly expressed, PILRβ activation could either synergize with or compete against TREM2-DAP12 signals depending on cellular context and ligand availability[8].
In Parkinson's disease and frontotemporal dementia, chronic neuroinflammation mediated by activated microglia contributes to neuronal damage. PILRβ's activating function may amplify inflammatory cytokine production (TNF-α, IL-1β, IL-6) through DAP12-Syk-NF-κB signaling when microglial activation becomes dysregulated[4:2].
The PILR receptor system represents a potential immunotherapeutic target for neurodegeneration. Strategies under investigation include:
These approaches must be carefully balanced, as excessive microglial activation can exacerbate neuroinflammation[7:1].
Tabata S, Kuroki K, Wang J, et al. Biophysical characterization of O-glycosylated CD99 recognition by paired Ig-like type 2 receptors. Journal of Biological Chemistry. 2008. ↩︎ ↩︎ ↩︎
Fournier N, Chalus L, Durand I, et al. FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells. Journal of Immunology. 2000. ↩︎ ↩︎ ↩︎
Sun Y, Senger K, Bhatt DK, et al. Innate immune receptor PILRA mediates HSV-1 entry through recognition of viral glycoprotein B sialylation. Proceedings of the National Academy of Sciences. 2020. ↩︎ ↩︎
Salminen A, Kaarniranta K, Kauppinen A. Innate immunity meets neuroinflammation: the immunoregulatory role of PILR family in Alzheimer's disease. Journal of Neuroinflammation. 2022. ↩︎ ↩︎ ↩︎
Satoh T, Arii J, Suenaga T, et al. PILRα is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell. 2008. ↩︎
Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nature Genetics. 2019. ↩︎
Rathore N, Bhatt DK, et al. Paired immunoglobulin-like type 2 receptor alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease. PLoS Medicine. 2018. ↩︎ ↩︎
Ulland TK, Colonna M. TREM2 — a key player in microglial biology and Alzheimer disease. Nature Reviews Neurology. 2018. ↩︎